BRAUN HEMODIALYSIS CATHETER by B. BRAUN MEDICAL, INC.

B. Braun of America Inc. intends to introduce into interstate commerce the Braun Diacath Hemodialysis Catheters in lengths of 170 mm and 250mm. These have the same design and performance characteristics.

AI/ML Overview

Here's an analysis of the provided information, focusing on the acceptance criteria and study aspects you requested.

Based on the provided K952660 510(k) summary, it is evident that this document does not describe a study involving an AI or algorithmic device. This 510(k) is for a physical medical device: the Braun Diacath Hemodialysis Catheters.

Therefore, most of your requested information (related to AI performance, ground truth, expert review, sample sizes for AI training/testing, MRMC studies, etc.) is not applicable to this submission.

However, I can extract the information relevant to the safety and effectiveness of this physical device based on the provided text.

Analysis of K952660: Braun Diacath Hemodialysis Catheters

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria Category	Specific Criteria / Test	Reported Device Performance / Compliance
Biocompatibility	Compliance with Tripartite Guidance for contact duration.	B. Braun Medical certifies that biocompatibility tests recommended in the Tripartite Guidance for this category of contact duration will be completed for all materials. (Note: "will be completed" implies a commitment rather than reported results in this summary).
Sterility	Must meet required release specifications.	All finished products are tested and must meet all required release specifications before distribution. Included in "array of testing."
Pyrogenicity	Must meet required release specifications (Endotoxin/LAL Method).	All finished products are tested and must meet all required release specifications before distribution. Included in "array of testing."
Physical Testing	Defined by Quality Control Test Procedure documents; conform to product design specifications.	All finished products are tested and must meet all required release specifications before distribution. Included in "array of testing."
Visual Examination	Must meet required release specifications (in process and finished product).	All finished products are tested and must meet all required release specifications before distribution. Included in "array of testing."
Substantial Equivalence	Equivalent in materials, form, and intended use to predicate devices (K893439, K941851).	The Braun Diacath Hemodialysis Catheters are equivalent in materials, form, and intended use to the catheters currently marketed by Medical Components, Inc. and Neostar Medical Technologies, Inc. No new issues of safety or effectiveness raised.

Regarding the study that proves the device meets the acceptance criteria:

The document describes the quality control/manufacturing process rather than a specific clinical or performance study with a distinct "test set" as one would expect for an AI device. The proof comes from:

Internal Quality Control: "All finished products are tested and must meet all required release specifications before distribution."
Adherence to Established Procedures: "The testing instruction records for each of the individually required procedures are approved, released, distributed and revised in accordance with document control GMP's."
Certification of Biocompatibility: A commitment to complete recommended biocompatibility tests.
Argument for Substantial Equivalence: The primary "proof" for regulatory clearance is the demonstration of substantial equivalence to already marketed devices regarding materials, form, and intended use, with no new safety or effectiveness concerns.

As this is not an AI/algorithmic device, the following points are not applicable (N/A) or cannot be answered from the provided text:

Sample size used for the test set and the data provenance: N/A (Not an AI device; no separate "test set" in the AI sense involved in this summary). The "test set" here refers to individual finished product units subjected to QC testing.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts: N/A (No ground truth generation by experts for an AI algorithm). Test parameters are defined by internal quality control procedures.
Adjudication method (e.g., 2+1, 3+1, none) for the test set: N/A (No expert adjudication for an AI algorithm).
If a multi-reader multi-case (MRMC) comparative effectiveness study was done: No. This is a physical device, not an AI system.
If a standalone (i.e., algorithm only without human-in-the-loop performance) was done: No. This is a physical device, not an AI system.
The type of ground truth used (expert consensus, pathology, outcomes data, etc.): N/A (The "ground truth" for a physical device is its adherence to predefined physical, chemical, and biological specifications and performance parameters, established through standard testing methods, not expert consensus on interpretations).
The sample size for the training set: N/A (Not an AI device; no training set in the AI sense).
How the ground truth for the training set was established: N/A (Not an AI device).

Summary

Regulation Number and Section

§ 876.5540 Blood access device and accessories.

(a)
Identification. A blood access device and accessories is a device intended to provide access to a patient's blood for hemodialysis or other chronic uses. When used in hemodialysis, it is part of an artificial kidney system for the treatment of patients with renal failure or toxemic conditions and provides access to a patient's blood for hemodialysis. The device includes implanted blood access devices, nonimplanted blood access devices, and accessories for both the implanted and nonimplanted blood access devices.(1) The implanted blood access device is a prescription device and consists of various flexible or rigid tubes, such as catheters, or cannulae, which are surgically implanted in appropriate blood vessels, may come through the skin, and are intended to remain in the body for 30 days or more. This generic type of device includes various catheters, shunts, and connectors specifically designed to provide access to blood. Examples include single and double lumen catheters with cuff(s), fully subcutaneous port-catheter systems, and A-V shunt cannulae (with vessel tips). The implanted blood access device may also contain coatings or additives which may provide additional functionality to the device.
(2) The nonimplanted blood access device consists of various flexible or rigid tubes, such as catheters, cannulae or hollow needles, which are inserted into appropriate blood vessels or a vascular graft prosthesis (§§ 870.3450 and 870.3460), and are intended to remain in the body for less than 30 days. This generic type of device includes fistula needles, the single needle dialysis set (coaxial flow needle), and the single needle dialysis set (alternating flow needle).
(3) Accessories common to either type include the shunt adaptor, cannula clamp, shunt connector, shunt stabilizer, vessel dilator, disconnect forceps, shunt guard, crimp plier, tube plier, crimp ring, joint ring, fistula adaptor, and declotting tray (including contents).
(b)
Classification. (1) Class II (special controls) for the implanted blood access device. The special controls for this device are:(i) Components of the device that come into human contact must be demonstrated to be biocompatible. Material names and specific designation numbers must be provided.
(ii) Performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(A) Pressure versus flow rates for both arterial and venous lumens, from the minimum flow rate to the maximum flow rate in 100 milliliter per minute increments, must be established. The fluid and its viscosity used during testing must be stated.
(B) Recirculation rates for both forward and reverse flow configurations must be established, along with the protocol used to perform the assay, which must be provided.
(C) Priming volumes must be established.
(D) Tensile testing of joints and materials must be conducted. The minimum acceptance criteria must be adequate for its intended use.
(E) Air leakage testing and liquid leakage testing must be conducted.
(F) Testing of the repeated clamping of the extensions of the catheter that simulates use over the life of the device must be conducted, and retested for leakage.
(G) Mechanical hemolysis testing must be conducted for new or altered device designs that affect the blood flow pattern.
(H) Chemical tolerance of the device to repeated exposure to commonly used disinfection agents must be established.
(iii) Performance data must demonstrate the sterility of the device.
(iv) Performance data must support the shelf life of the device for continued sterility, package integrity, and functionality over the requested shelf life that must include tensile, repeated clamping, and leakage testing.
(v) Labeling of implanted blood access devices for hemodialysis must include the following:
(A) Labeling must provide arterial and venous pressure versus flow rates, either in tabular or graphical format. The fluid and its viscosity used during testing must be stated.
(B) Labeling must specify the forward and reverse recirculation rates.
(C) Labeling must provide the arterial and venous priming volumes.
(D) Labeling must specify an expiration date.
(E) Labeling must identify any disinfecting agents that cannot be used to clean any components of the device.
(F) Any contraindicated disinfecting agents due to material incompatibility must be identified by printing a warning on the catheter. Alternatively, contraindicated disinfecting agents must be identified by a label affixed to the patient's medical record and with written instructions provided directly to the patient.
(G) Labeling must include a patient implant card.
(H) The labeling must contain comprehensive instructions for the following:
(
1 ) Preparation and insertion of the device, including recommended site of insertion, method of insertion, and a reference on the proper location for tip placement;(
2 ) Proper care and maintenance of the device and device exit site;(
3 ) Removal of the device;(
4 ) Anticoagulation;(
5 ) Management of obstruction and thrombus formation; and(
6 ) Qualifications for clinical providers performing the insertion, maintenance, and removal of the devices.(vi) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices that include subcutaneous ports must include the following:
(A) Labeling must include the recommended type of needle for access as well as detailed instructions for care and maintenance of the port, subcutaneous pocket, and skin overlying the port.
(B) Performance testing must include results on repeated use of the ports that simulates use over the intended life of the device.
(C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use.
(vii) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices with coatings or additives must include the following:
(A) A description and material characterization of the coating or additive material, the purpose of the coating or additive, duration of effectiveness, and how and where the coating is applied.
(B) An identification in the labeling of any coatings or additives and a summary of the results of performance testing for any coating or material with special characteristics, such as decreased thrombus formation or antimicrobial properties.
(C) A Warning Statement in the labeling for potential allergic reactions including anaphylaxis if the coating or additive contains known allergens.
(D) Performance data must demonstrate efficacy of the coating or additive and the duration of effectiveness.
(viii) The following must be included for A-V shunt cannulae (with vessel tips):
(A) The device must comply with Special Controls in paragraphs (b)(1)(i) through (v) of this section with the exception of paragraphs (b)(1)(ii)(B), (b)(1)(ii)(C), (b)(1)(v)(B), and (b)(1)(v)(C), which do not apply.
(B) Labeling must include Warning Statements to address the potential for vascular access steal syndrome, arterial stenosis, arterial thrombosis, and hemorrhage including exsanguination given that the device accesses the arterial circulation.
(C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use.
(2) Class II (performance standards) for the nonimplanted blood access device.
(3) Class II (performance standards) for accessories for both the implanted and the nonimplanted blood access devices not listed in paragraph (b)(4) of this section.
(4) Class I for the cannula clamp, disconnect forceps, crimp plier, tube plier, crimp ring, and joint ring, accessories for both the implanted and nonimplanted blood access device. The devices subject to this paragraph (b)(4) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.